Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;148(14):1795-1805.
doi: 10.1017/s0031182021001347. Epub 2021 Aug 9.

A historical and systematic overview of Ascaris vaccine development

Ana Clara Gazzinelli-Guimarães  1 , Pedro Gazzinelli-Guimarães  2 , Jill E Weatherhead  3   4   5
Affiliations

A historical and systematic overview of Ascaris vaccine development

Ana Clara Gazzinelli-Guimarães et al. Parasitology. 2021 Dec.

Abstract

Ascariasis is the most prevalent helminth infection in the world and leads to significant, life-long morbidity, particularly in young children. Current efforts to control and eradicate ascariasis in endemic regions have been met with significant challenges including high-rates of re-infection and potential development of anthelminthic drug resistance. Vaccines against ascariasis are a key tool that could break the transmission cycle and lead to disease eradication globally. Evolution of the Ascaris vaccine pipeline has progressed, however no vaccine product has been brought to human clinical trials to date. Advancement in recombinant protein technology may provide the first step in generating an Ascaris vaccine as well as a pan-helminthic vaccine ready for human trials. However, several roadblocks remain and investment in new technologies will be important to develop a successful human Ascaris vaccine that is critically needed to prevent significant morbidity in Ascaris-endemic regions around the world.

Keywords: Ascariasis; helminths; recombinant proteins; vaccine development.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

None
Graphical abstract
Fig. 1.
Fig. 1.
Geographic distribution of Ascaris-associated DALYs per 100 000 from the Global Burden of Disease Collaborative Network, 2019. Institute for Health Metrics and Evaluation (IHME), Seattle, United States, 2020 (http://www.healthdata.org/results/gbd_summaries/2019/ascariasis-level-4-cause).
Fig. 2.
Fig. 2.
Years of life lost (YLL) and years of healthy life lost to disability (YLD) from ascariasis globally from the Global Burden of Disease Collaborative Network, 2019. Institute for Health Metrics and Evaluation (IHME), Seattle, United States, 2020 (http://www.healthdata.org/results/gbd_summaries/2019/ascariasis-level-4-cause).
Fig. 3.
Fig. 3.
Timeline of Ascaris targets and animal models used in the Ascaris vaccine development process. To date there have been no vaccine candidates that have moved from pre-clinical animal models into human clinical trials. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Anthony RM, Rutitzky LI, Urban JF,Jr, Stadecker MJ and Gause WC (2007) Protective immune mechanisms in helminth infection. Nature Reviews Immunology 7, 975–987. - PMC - PubMed
    1. Arean VM and Crandall CA (1962) The effect of immunization on the fate of injected second stage Ascaris lumbricoides larvae in the rabbit. The American Journal of Tropical Medicine and Hygiene 11, 369–379. - PubMed
    1. Betson M and Stothard JR (2016) Ascaris lumbricoides or Ascaris suum: what's in a name?. The Journal of Infectious Diseases 213, 1355–1356. - PMC - PubMed
    1. Chen D, Colditz IG, Glenn GM and Tsonis CG (2002) Effect of transcutaneous immunization with co-administered antigen and cholera toxin on systemic and mucosal antibody responses in sheep. Veterinary Immunology and Immunopathology 86, 177–182. - PubMed
    1. Chen N, Yuan ZG, Xu MJ, Zhou DH, Zhang XX, Zhang YZ, Wang XW, Yan C, Lin RQ and Zhu XQ (2012) Ascaris suum enolase is a potential vaccine candidate against ascariasis. Vaccine 30, 3478–3482. - PubMed

Publication types